Similar articles

• Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.

  DiMarco JP, Flaker G, Waldo AL, Corley SD, Greene HL, Safford RE, Rosenfeld LE, Mitrani G, Nemeth M; AFFIRM Investigators. DiMarco JP, et al. Am Heart J. 2005 Apr;149(4):650-6. doi: 10.1016/j.ahj.2004.11.015. Am Heart J. 2005. PMID: 15990748 Clinical Trial.
• Contra: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Caveats regarding use of oral anticoagulant therapy among elderly patients with atrial fibrillation.

  Hylek EM. Hylek EM. Thromb Haemost. 2008 Jul;100(1):16-7. doi: 10.1160/TH08-06-0343. Thromb Haemost. 2008. PMID: 18612532 No abstract available.
• Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.

  Douketis JD, Arneklev K, Goldhaber SZ, Spandorfer J, Halperin F, Horrow J. Douketis JD, et al. Arch Intern Med. 2006 Apr 24;166(8):853-9. doi: 10.1001/archinte.166.8.853. Arch Intern Med. 2006. PMID: 16636210 Clinical Trial.
• [Thromboembolism in non-rheumatic atrial fibrillation].

  Pengo V. Pengo V. Haematologica. 2001 Sep;86(9 Suppl):5-11. Haematologica. 2001. PMID: 11759619 Review. Italian. No abstract available.
• Oral anticoagulant therapy in patients with atrial fibrillation.

  Pengo V. Pengo V. Semin Vasc Med. 2003 Aug;3(3):333-8. doi: 10.1055/s-2003-44469. Semin Vasc Med. 2003. PMID: 15199467 Review.